None of the treatments increased the cytotoxicity markers granzyme B and perforin at the time of evaluation, which does not mean that in the face of direct activation with the tumor cell, a tumor-specific cytotoxic activity cannot be evidenced. This evidence concerns the gene PRF1 and neoplasm.